I was originally looking at my US semiconductor warehouse, $MU, which fell 7.5%, SNDK fell nearly 10%, and fees fell 2.12%. However, when I turned around, I saw Moderna surge from around $63 to $174.38, with a daily increase of 176.97%. But today, the market started to calculate another account. As of just now, MRNA fell to $140, with a drop of 17.75%. The intraday high was $166.73, and the intraday low was $136.66, with a trading volume of nearly 49 million shares. Yesterday, those who were chasing around $174 had a maximum daily loss of over 20%. Clinical results can change a company's long-term value, but short-term prices often take into account the possibility of many years in the future The news of MRNA this time is not just an ordinary clinical benefit. Its personalized mRNA cancer therapy in collaboration with Merck has reached the primary endpoint in a high-risk melanoma phase III trial. It is to make vaccines based on the genetic characteristics of each patient's tumor, and then cooperate with MSD's Keytruda to reduce the risk of cancer recurrence and spread after surgery. MSD rose 12.6% yesterday, and today it is basically flat at around 152.22 dollars. What really changed is the way the market views Moderna. In the past few years, it has been regarded as a vaccine company with COVID-19 dividend and declining revenue. Now the market is beginning to believe that mRNA can not only prevent infectious diseases, but also become a tumor treatment platform When I saw this extreme market trend, I casually searched for MRNA in @ bitget Bitget US stock market and conducted a small limit order test with 1000 USDC. I didn't directly chase the market price, but hung the price near the buy price to observe the response of order changes and cancellations. The processing of small orders was relatively smooth without obvious lag. For someone like me who usually watches cryptocurrency market trends on Bitget, when I suddenly see an opportunity in the US stock market, I can directly switch to check the market position or small trial order funds without having to switch between several platforms. It is indeed more convenient, but I am still more accustomed to using limit orders, especially MRNA, stocks that rise and fall by tens of dollars a day. Whether the market order is fast or not, and whether the price is comfortable after the transaction is fast, is another matter According to the latest $140 calculation, Moderna's current market value is about $57.3 billion, which is still more than $32 billion compared to the $25 billion before the news was announced. The problem is that the company's current announcement is only the top line results, specific improvement in efficacy, complete safety data, FDA review progress, and final commercial price have not been fully implemented in the market. Now, it is not just pricing a melanoma therapy, but also pre positioning the entire mRNA tumor platform. The popularity of the betting sector has also started to cool down. Yesterday, XBI Biotechnology ETF rose 5.9%, today fell about 2.4%, and BioNTech also fell about 2.3% today, indicating that profit taking is not only happening on MRNA stock On the other hand, MU rebounded 2.15% today, SNDK rebounded 1.92%, and fees were basically flat. Yesterday, funds rushed from chips to pharmaceuticals, and today it has become a profit market for pharmaceutical digestion. Chips are also re evaluating prices. My opinion is simple. The clinical breakthrough of MRNA is real, and market re valuation is reasonable. But if it rises by 177% one day and falls by nearly 18% the next day, it means that what is being traded now is not only the value of drugs, but also the sentiment of short covering and capital rotation. I will not think it is cheap just because it fell by 18%, nor will I rush to do empty handed semiconductor positions because it rose too much yesterday. I did not move MRNA. I will continue to observe the table and wait for complete clinical data to come out before looking at this new 32 billion US dollars. Is it an early discovery of value or has the story been told BitgetTradFi Contract Recommendation Officer